Comparing robotic and assistant-controlled techniques for gastric cancer surgery
Official title: Clinical Outcomes of Full Robotic Instrumentation Versus Assistant Controlled Laparoscopic Instrumentatin in Robotic Distal Gastrectomy: Randomized Pilot Study
Run by Gangnam Severance Hospital · NCT06841484 · Data updated 2026-11-12
This study is testing whether using a robot or having an assistant control the tools during gastric cancer surgery leads to better results for patients.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 20 Years and up |
| Sex | All |
| Enrollment | 36 (estimated) |
| Sponsor | Gangnam Severance Hospital Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Seoul) |
| Status | Recruiting |
| Started | February 1, 2025 |
| Main results expected | January 1, 2026 |
| Study ends | March 31, 2026 |
| Registry record updated | February 24, 2025 |
| Trial ID | NCT06841484 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include adults with confirmed gastric adenocarcinoma who are undergoing robotic radical distal gastrectomy and have an ASA score of 3 or below.
✕Probably not a fit
Patients under 19 years of age, those with stage IV gastric cancer, or those who have received preoperative chemotherapy or radiotherapy may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This pilot study aims to evaluate the effectiveness of two surgical approaches for robotic distal gastrectomy: full robotic instrumentation versus assistant-controlled laparoscopic instrumentation. By analyzing the outcomes of these techniques, the study seeks to identify which method enhances surgical efficiency, reduces costs, and improves patient outcomes. The findings may provide valuable insights that could influence future surgical practices in treating gastric cancer.
Why it matters
Potential benefit: If successful, this study could lead to improved surgical techniques that enhance recovery and outcomes for patients with gastric cancer.
How similar studies have gone: While this study explores a specific comparison, similar approaches in robotic surgery have shown promise in enhancing surgical outcomes, suggesting potential for success.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Patients with histologically confirmed gastric adenocarcinoma prior to surgery. 2. Patients who have undergone a complete (R0) resection. 3. Patients with an ASA (American Society of Anesthesiologists) score of 3 or below. 4. Patients undergoing robotic radical distal gastrectomy. Exclusion Criteria: 1. Patients under 19 years of age. 2. Patients who have received preoperative chemotherapy or radiotherapy. 3. Patients diagnosed with stage IV gastric cancer due to distant metastasis. 4. Patients diagnosed with malignancies other than gastric cancer. 5. Patients scheduled to undergo total gastrectomy. 6. Patients requiring total omentectomy.
Where it's running
-
GangnamSeveranceHospital
Seoul, South Korea Recruiting
Study contacts
- Study coordinator: In Gyu Kwon
- Email: gsirb@yuhs.ac
- Phone: 82-2-2019-4601
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
CG-7321: a first-in-human test in advanced solid tumors
We’re testing CG-7321 alone and with fulvestrant to see if it’s safe and tolerable in adults with advanced solid tumors.
-
Neoadjuvant trastuzumab, durvalumab, and FLOT for HER2-positive gastric or GEJ cancer
This study tests a pre-surgery treatment combining trastuzumab, durvalumab, and FLOT for patients with HER2-positive locally advanced gastric or gastroesophageal junction cancer to see how many achieve complete tumor disappearance.
-
Integrated genomic and clinical database for cancer biomarker discovery
Researchers are building a combined genomic and clinical database at Samsung Medical Center to test biomarkers for cancer diagnosis, treatment choice, and predicting how well treatments work.
-
Adding 2141-V11 to standard therapy for advanced esophageal, gastric, or gastroesophageal junction cancer
This study tests whether adding the drug 2141-V11 to standard anti-PD-1 therapy (with or without 5-FU) is safe for adults with advanced or metastatic esophageal, gastric, or gastroesophageal junction adenocarcinoma.
-
Guaraná Supplement for Cancer-Related Fatigue in People Undergoing Treatment
This study tests whether taking guaraná capsules helps reduce cancer-related fatigue and improve quality of life in adults with breast, lung, colorectal, or gastric cancer who are actively receiving treatment.
-
ABBV-253 in adults with advanced solid tumors
This study tests ABBV-253 to see if it is safe, how it affects the cancer, and how the drug moves in the body for adults with advanced solid tumors.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.